

| | | | |
|---|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney Docket No. 14875-0163US1 | Application No. 10/582,176 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) | | Applicant Kiyotaka Nakano <i>et al.</i> | |
| | | Filing Date April 18, 2007 | Group Art Unit 1641 |
| (37 CFR §1.98(b)) | | | |

U.S. Patent Documents

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|----------------------|-------|----------|----------------------------|
| | 1 | 4,946,778 | 08/07/1990 | Ladner <i>et al.</i> | | | |
| | 2 | 5,789,554 | 08/04/1998 | Leung <i>et al.</i> | | | |
| | 3 | 7,456,260 | 11/25/2008 | Rybak <i>et al.</i> | | | |
| | 4 | 2008/0248037 | 10/09/2008 | Li <i>et al.</i> | | | |
| | 5 | 2009/0117097 | 05/07/2009 | Igawa <i>et al.</i> | | | |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|------------------|----|
| | | | | | | | Yes | No |
| | 6 | WO 99/12973 | 03/18/1999 | WIPO | | | English abstract | |
| | 7 | WO 01/87337 | 11/22/2001 | WIPO | | | | |
| | 8 | WO 2004/003019 | 01/08/2004 | WIPO | | | | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|--|
| | 9 | ARNDT <i>et al.</i> , "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment," <i>Biochemistry</i> , 37:12918-12926 (1998) |
| | 10 | DUFNER <i>et al.</i> , "Harnessing phage and ribosome display for antibody optimization," <i>Trends Biotechnol.</i> , 24(11):523-529 (2006) |
| | 11 | ICHIKAWA <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> , 7:954-960 (2001) |
| | 12 | KUMAR <i>et al.</i> , "Molecular cloning and expression of the Fabs of human autoantibodies in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 275(41):35129-35136 (2000) |
| | 13 | MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999) |
| | 14 | PAUL, <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993) |
| | 15 | SMITH-GILL <i>et al.</i> , "Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens," <i>The Journal of Immunology</i> , 139:4135-4144 (1987) |
| | 16 | SONG <i>et al.</i> , "Light chain of natural antibody plays a dominant role in protein antigen binding," <i>Biochemical and Biophysical Research Communications</i> , 268:390-394 (2000) |
| | 17 | WAKELEE <i>et al.</i> , "Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors," <i>Ann. Oncol.</i> On-line publication (7/24/2009) |
| | 18 | WARD <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989) |
| | 19 | WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994) |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|---|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney Docket No. 14875-0163US1 | Application No. 10/582,176 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) | | Applicant Kiyotaka Nakano <i>et al.</i> | |
| | | Filing Date April 18, 2007 | Group Art Unit 1641 |
| (37 CFR §1.98(b)) | | | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|--|
| | 20 | YAGITA <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> , 95:777-783 (2004) |
| | 21 | FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 16, 2009 in U.S. App. Ser. No. 10/550,934, filed September 10, 2009, 75 pages |
| | 22 | FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 8, 2009 in U.S. App. Ser. No. 11/913,229, filed August 4, 2009, 1 page |
| | 23 | U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed September 15, 2009, 22 pages |
| | 24 | EPO EXAMINER TERESA SOMMERFELD, European Search Report for App. Ser. No. EP 06 74 6578, dated June 25, 2009, 2 pages |
| | 25 | FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages |
| | 26 | KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages |
| | 27 | U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/582,654, mailed September 1, 2009, 36 pages |
| | 28 | U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed September 11, 2009, 24 pages |
| | 29 | U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/257,864, mailed February 1, 2006, 14 pages |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |